Matinas BioPharma Holdings (MTNB) Operating Margin (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly Operating Margin of 854.23% for Q2 2023, down 29685.0% year-over-year from N/an in Q2 2022, and up 42.65% quarter-over-quarter from 1489.6% in Q1 2023.
Matinas BioPharma Holdings (MTNB) Operating Margin (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Operating Margin for 8 consecutive years, with 854.23% the latest figure, recorded in Q2 2023.
- In Q2 2023, Operating Margin fell 29685.0% year-over-year to 854.23%; the TTM figure through Dec 2023 stood at 2168.43% (down 139729.0% YoY), while the FY2023 annual figure was 2168.43%, down 139710.0% from the prior year.
- Operating Margin rose to 854.23% in Q2 2023 per MTNB's latest filing, from 1489.6% in the prior quarter.
- Across five years, Operating Margin topped out at 2016293.39% in Q4 2021 and bottomed at 19059.52% in Q1 2021.
- Historically, Operating Margin has averaged 199274.87% across 5 years, with a median of 705.81% in 2023.
- Annual changes were most pronounced in 2021 — Operating Margin soared 200596620 bps — and 2022, when it plunged 201680892 bps.
- Matinas BioPharma Holdings' Operating Margin stood at 5033.49% in 2019, then surged by 305 bps to 10327.19% in 2020, then surged by 19424 bps to 2016293.39% in 2021, then tumbled by 100 bps to 515.52% in 2022, then tumbled by 66 bps to 854.23% in 2023.
- Business Quant data shows MTNB's Operating Margin at 854.23% in Q2 2023, 1489.6% in Q1 2023, and 515.52% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Matinas BioPharma Holdings | 1.20 Mn | 385,035.87 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -854.23% |
| Mar 31, 2023 | -1,489.60% |
| Dec 31, 2022 | -515.52% |
| Sep 30, 2022 | -513.83% |
| Jun 30, 2022 | -557.38% |
| Dec 31, 2021 | 2,016,293.39% |
| Mar 31, 2021 | -19,059.52% |
| Dec 31, 2020 | 10,327.19% |
| Sep 30, 2020 | -5,848.30% |
| Jun 30, 2019 | -5,033.49% |
| Jun 30, 2018 | -3,791.13% |
| Mar 31, 2018 | -13,764.74% |
| Dec 31, 2017 | -10,311.72% |
| Sep 30, 2017 | -7,589.85% |
| Jun 30, 2017 | -8,854.73% |
| Mar 31, 2017 | -29,976.78% |
| Sep 30, 2015 | -3,606.48% |
| Jun 30, 2015 | -3,119.21% |
| Mar 31, 2015 | -4,456.62% |